Immatics N.V. (IMTX) announced updated findings on Thursday from the Phase 1b trial of its ACTengine cell therapy, IMA203, targeting melanoma patients.
The ACTengine approach involves customizing treatment by extracting a patient’s immune cells, genetically engineering them to attack cancerous tumors, and reinfusing them back into the patient.
During the Phase 1b dose expansion segment of the trial, patients with advanced and previously treated metastatic melanoma received IMA203. The trial data demonstrated notable improvements in median progression-free survival (PFS) and overall survival (OS) when compared with results from the earlier Phase 1a dose escalation study.
Moreover, IMA203 sustained a commendable safety profile, with no Grade 5 adverse effects linked to the treatment.
With these encouraging results, Immatics intends to advance directly to a pivotal Phase 3 trial, named SUPRAME, aimed at metastatic melanoma patients. This next phase is set to commence in December, with an interim analysis scheduled for early 2026. Immatics has plans to file a Biologics License Application (BLA) in early 2027.
